BP-100-2.01

BP-100-2.01 is Bio-Path’s lead liposomal siRNA drug candidate. The scientific name for BP-100-2.01 is liposomal FAX. FAX plays a significant role in cell survival, migration and invasion. It is overexpressed in ovarian cancer and is predictive of poor clinical outcome. FAK is also overexpressed in a large number of other human tumors including colon, breast, thyroid, and head and neck cancers. BP-100-2.01 demonstrates anti-tumor activity in preliminary ovarian cancer xenograft mouse models.